Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression
Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF), a Toronto-based psychedelics company, is launching a randomized clinical trial using psilocybin for adults with treatment-resistant depression.
